• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 20, 2016

View Archived Issues

Sarepta Therapeutics soars on eteplirsen's surprise accelerated approval in DMD

After months of speculation, Sarepta Therapeutics Inc. hit pay dirt, gaining accelerated approval – and a rare pediatric disease priority review voucher (PRV) – from the FDA for its Duchenne muscular dystrophy (DMD) drug, eteplirsen, branded Exondys 51. Read More

Other news to note

Sutro Biopharma Inc., of San Francisco, presented findings from two studies of investigational antibody drug conjugates (ADC) that it developed to target CD74, a protein highly expressed in hematologic malignancies. Read More

In the clinic

Seattle Genetics Inc., of Bothell, Wash., said it enrolled the first patient in a multicenter phase I trial of SGN-CD123A to treat relapsed or refractory acute myeloid leukemia. Read More

Vical, Astellas report miss in kidney transplant study with CMV vaccine

Vical Inc. and partner Astellas Pharma Inc. remain hopeful for positive data from an ongoing phase III study testing cytomegalovirus (CMV) vaccine ASP0113 in hematopoietic stem cell transplant (HCT) recipients, set to read out late next year, despite the product's phase II miss in solid organ transplant patients. Read More

United Nations set to address antimicrobial resistance threat

LONDON – The threat of antimicrobial resistance (AMR) reaches the top of the international agenda tomorrow, when the United Nations (UN) general assembly is due to hold a high level meeting to discuss the issue and approve a resolution to tackle the problem on a broad front. Read More

Toolgen wins critical CRISPR patent in Korea

SHANGHAI – Asia's contender in the CRISPR patent battle is now a step closer to seeing global IP claims validated. Toolgen Inc., of Seoul, South Korea had two patent applications granted by the Korea Intellectual Property Office covering genome editing using the CRISPR platform. Read More

NIH: Final clinical studies registration rule is retroactive

Two years and more than 900 comments to the docket later, the NIH has published the final rule for clinical trial registration at clinicaltrials.gov, declaring the rule will go into force on Jan. 18, 2017. Read More

Teva sees pridopidine slowing HD progression in phase II study

Teva Pharmaceutical Industries Ltd. reported on Monday that a phase II trial of its experimental Huntington's disease (HD) drug pridopidine showed a statistically significant impact on disease progression at 52 weeks vs. placebo. Read More

BsUFA II tradeoffs could delay some biosimilar guidances

FDA commitments in the BsUFA II goals letter to improve communication, transparency and staffing are getting high marks from industry, which sees those steps as essential to bettering the review of biosimilars for the U.S. market. Read More

Financings

TVM Life Science Ventures VII said it has made an investment in Aurka Pharma Inc., of Montreal. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe